Tandem Diabetes Care Inc

The U.S. Food and Drug Administration on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older, making it the first wearable in the U.S. to continuously monitor ketone levels and the first global system to track blood sugar and ketones simultaneously in a single unit. The agency granted marketing authorization via the De Novo pathway for new low-to-moderate-risk devices, following a review of six clinical studies involving over 600 participants that demonstrated accurate tracking of clinically significant ketone variations. The sensor, which offers up to 10 days of wear, alerts users when ketones rise, replacing single-point urine or blood tests. Abbott is working with pump companies to integrate the sensor with automated insulin delivery systems, expecting compatibility with iLet from Beta Bionics Inc and twiist from Sequel Med Tech by the end of this year, and with systems from Insulet Corp and Tandem Diabetes Care Inc by 2027, alongside an exclusive integration with MiniMedGroup Inc for smart dosing systems. William Blair analyst Brandon Vazquez noted the clearance may create a new competitive dynamic for DexCom Inc shares, with the sensor likely most competitive in the pediatric population once integrated with AID pumps next year.

Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration pairs Tandem's advanced AutoBolus-enabled AID algorithm with one of Europe's most widely used CGM platforms, potentially broadening its addressable user base and deepening product stickiness in key European markets. The move supports the company's near-term interoperability and international growth catalyst, though it does not fundamentally change execution risk around commercial transformation or pressure from new entrants in the U.S. pump market. Tandem's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029, requiring 10.3% yearly revenue growth and an earnings increase of about $158 million from a current loss of $94.5 million.

Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology now integrates with Abbott's FreeStyle Libre 3 Plus continuous glucose monitor across five European countries. The company's annual revenue exceeds $1,027.535 million, yet its share price has fallen 28.49% year to date to $15.41. A popular investor narrative on Simply Wall St sets a fair value of $29.20 per share, suggesting the stock is 47.2% undervalued based on long-term earnings potential. Broader pharmacy channel expansion is expected to lower out-of-pocket costs and increase pump adoption, supporting future revenue growth and margin expansion. However, the outlook also carries execution and competitive risks, including rising pump competition and flat renewal expectations.

Evercore ISI analyst Vijay Kumar reduced the firm's price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. The updated target was included in the firm's second-quarter outlook for the MedTech, Life Sciences Tools, and Diagnostics industries. Evercore ISI noted that sector conditions remain supported by relatively healthy procedure volumes and capital spending trends. Separately, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor in five countries, with broader European availability expected in 2026.

Tandem Diabetes Care is positioned for growth driven by rising diabetes prevalence and connected care adoption, but faces macroeconomic and execution risks. The company is expanding its addressable market with Control-IQ+ for type 1 and type 2 diabetes and transitioning to a pay-as-you-go reimbursement model in the U.S. pharmacy channel, which represented 6% of U.S. sales in first-quarter 2026. Management reaffirmed 2026 guidance for revenues of about $1.065 billion to $1.085 billion, gross margin of about 56% to 57%, and adjusted EBITDA margin of about 5% to 6%. Tandem Diabetes ended the first quarter with $570.3 million in cash, cash equivalents, and short-term investments, and no short-term debt. The Zacks Consensus Estimate for 2026 revenues is $1.08 billion, implying 6% growth, while the loss per share estimate stands at 72 cents. The stock carries a Zacks Rank #3.

GoodRx reported first-quarter revenues of $194 million, down 4.4% year on year, exceeding analysts' expectations by 4.9%. The company also provided full-year revenue guidance that slightly topped estimates. Among the seven healthcare technology stocks tracked, GoodRx posted the slowest revenue growth, while the group overall beat consensus revenue estimates by 1.6% and issued in-line next-quarter guidance. Omnicell delivered the best performance with revenues of $309.9 million, up 14.9% year on year, and Hims & Hers Health was the weakest, with revenues of $608.1 million missing estimates by 1.4%. Astrana Health achieved the fastest revenue growth at 55.6% year on year, and Tandem Diabetes raised its full-year guidance the most among peers.